ABIOMED, Inc. (NASDAQ:ABMD) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On July27, 2017, we issued a press release reporting our financial results for our first quarter ended June30, 2017. A copy of the press release is set forth as Exhibit 99.1 and is incorporated herein by reference. The information contained in this report shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Act of 1934, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.
| Item 2.02 | Financial Statements and Exhibits. |
(d)Exhibits.
|
Exhibit |
Description |
| 99.1 | Press release dated July 27, 2017. |
ABIOMED INC ExhibitEX-99.1 2 d413120dex991.htm EXHIBIT 99.1 Exhibit 99.1 Exhibit 99.1 ABIOMED ANNOUNCES Q1 FY 2018 REVENUE OF $132.5 MILLION,…To view the full exhibit click here
About ABIOMED, Inc. (NASDAQ:ABMD)
ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.